Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate documented
October 13th, 2006
According to a study from the United States, the cancer therapeutic agent imatinib mesylate (Gleevac) is cardiotoxic. "Gleevec is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that imatinib-treated mice develop left ventricular contractile dysfunction," wrote R. Kerkela and colleagues, Thomas Jefferson University. "Transmission electron micrographs from humans and mice treated with imatinib show mitochondrial abnormalities and accumulation of membrane whorls in both vacuoles and the...
Source: Medicine & Law Weekly (2006-10-13)
|
